LONG MINI FUTURE WARRANT - NOVO-NORDISK B | Market Closed - Euronext Paris 10:00:01 31/05/2024 pm IST | ||
| 200.7 EUR | +1.17% |
|
| 1 month | +3.07% | ||
| 3 months | +16.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 200.8 | +1.20% |
| 30/24/30 | 198.4 | +0.75% |
| 29/24/29 | 196.9 | -0.36% |
| 28/24/28 | 197.6 | -0.66% |
| 27/24/27 | 199 | -0.92% |
Real-time Euronext Paris
Last update May 31, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| C68XH | |
| ISIN | NL0014740920 |
| Date issued | 21/04/2020 |
| Strike | 180.7 kr |
| Maturity | Unlimited |
| Parity | 0.5 : 1 |
| Emission price | 10.77 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 204.5 € |
|---|---|
| Lowest since issue | 5.3 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- C68XH Certificat
